Company Encyclopedia
View More
name
SHANGHAI SERUM BIO-TECHNOLOGY
688163.SH
Shanghai Serum Bio-Technology Co., Ltd. engages in the research, development, production, operation, and sale of antitoxin and antiserum products in China. It offers equine anti-tetanus immunoglobulin, anti-venin, and anti-rabies serum products. The company was founded in 1999 and is based in Shanghai, China.
1.568 T
688163.SHMarket value -Rank by Market Cap -/-

Financial Score

22/11/2025 Update
C
BiotechnologyIndustry
Industry Ranking60/81
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE4.07%C
    • Profit Margin23.15%A
    • Gross Margin80.60%A
  • Growth ScoreC
    • Revenue YoY-0.27%D
    • Net Profit YoY-10.55%D
    • Total Assets YoY1.40%C
    • Net Assets YoY0.98%C
  • Cash ScoreC
    • Cash Flow Margin431.94%C
    • OCF YoY-0.27%D
  • Operating ScoreD
    • Turnover0.17D
  • Debt ScoreA
    • Gearing Ratio3.14%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    SHANGHAI SERUM BIO-TECHNOLOGY released its performance for the first three quarters, with a net profit attributable to the parent company of 64.21 million yuan, a year-on-year increase of 2.01%

    According to the Zhitong Finance APP, SHANGHAI SERUM BIO-TECHNOLOGY disclosed its third-quarter report for 2025. The company achieved revenue of 175 million yuan in the first three quarters, a year-on-year increase of 1.07%; net profit attributable to shareholders was 64.21 million yuan, a year-on-year increase of 2.01%; net profit excluding non-recurring items was 56.44 million yuan, a year-on-year increase of 12.15%; basic earnings per share were 0.59 yuan

    Zhitong·
    SH
    688163
    -5.21%
    Zhitong·
    SH
    688163
    -5.21%

    Zhitong A-share lock-up release overview | September 11

    On September 11th, a total of 3 listed companies had their restricted shares unlocked, with a total market value of approximately 2.038 billion yuan. The specific situation of the restricted share unlock today is as follows: Stock Abbreviation Stock Code Restricted Share Type Unlocked Shares LCE 002036 Equity Incentive Restricted Circulation 50,000 QINGMU 301110 Extended Restricted Lock-up Period Circulation 30.75 million SHANGHAI SERUM BIO-TECHNOLOGY 688163 6.3848 million

    Zhitong·
    SZ
    002036
    -3.82%
    SZ
    301110
    +0.79%
    SH
    688163
    -5.21%
    Zhitong·
    SZ
    002036
    -3.82%
    SZ
    301110
    +0.79%
    SH
    688163
    -5.21%

    SHANGHAI SERUM BIO-TECHNOLOGY released its semi-annual performance, with a net profit attributable to the parent company of 32.98 million yuan, a year-on-year increase of 2.07%

    According to the Zhitong Finance APP, SHANGHAI SERUM BIO-TECHNOLOGY disclosed its semi-annual report for 2025. During the reporting period, the company achieved revenue of 101 million yuan, a year-on-year increase of 2.82%; net profit attributable to shareholders was 32.98 million yuan, a year-on-year increase of 2.07%; net profit excluding non-recurring items was 28.53 million yuan, a year-on-year increase of 25.08%; basic earnings per share were 0.30 yuan. The company plans to distribute a cash dividend of 1.20 yuan (tax included) for every 10 shares to all shareholders

    Zhitong·
    SH
    688163
    -5.21%
    Zhitong·
    SH
    688163
    -5.21%

    SHANGHAI SERUM BIO-TECHNOLOGY: Has not conducted research related to AIDS vaccines

    SHANGHAI SERUM BIO-TECHNOLOGY stated on the interactive platform that the company has not conducted any research related to AIDS vaccines

    Zhitong·
    SH
    688163
    -5.21%
    Zhitong·
    SH
    688163
    -5.21%

    "Small and Beautiful" Stocks Exposed, 21 Stocks Listed

    According to data from Data Treasure, 21 non-ST stocks have a market value of less than 2 billion yuan, and their debt-to-asset ratio is below 40% at the end of the first quarter, with positive net profits for both 2024 and the first quarter of this year. Among them, Qilu Huaxin and Hengyu Environmental Protection have market values of less than 1.5 billion yuan, while SHANGHAI SERUM BIO-TECHNOLOGY and YBTI have the lowest debt-to-asset ratios, both below 10%. SHANGHAI SERUM BIO-TECHNOLOGY mainly engages in antitoxin and antiserum, while YBTI is involved in edible mushrooms, ham, and coffee businesses. AADRI's net profit surged nearly 28 times year-on-year, mainly engaged in architectural design and consulting

    Zhitong·
    SH
    688163
    -5.21%
    SH
    600883
    -5.54%
    SZ
    301167
    -4.96%
    Zhitong·
    SH
    688163
    -5.21%
    SH
    600883
    -5.54%
    SZ
    301167
    -4.96%